# iRegene raises RMB 260 million in Series C+ financing

On 2026-07-02, according to Xiniu Data, iRegene completed Series C+ financing, raising RMB 260 million. Investors were lead investor Chengdu Ke Venture Capital, participating investor Zhongxinjian Investment Ben, participating investor Xi Venture Capital, participating investor Dingtaixing, participating investor Xinjiye, participating investor Hongyi Capital, participating investor Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs.



Canonical: https://uniquebase.ai/news/48c7fbb5-da1d-4d8f-8891-16287b8388df
Stable identifier: 48c7fbb5-da1d-4d8f-8891-16287b8388df
Snapshot captured: 2026-10-20T18:19:32.670Z
English updated: 2026-10-20T18:21:37.336Z

## Connected profiles

- [Chengdu Ke Venture Capital](/institutions/chengdu-ke-venture-capital)
- [Dingtaixing](/institutions/dingtaixing)
- [Hongyi Capital](/institutions/UB-I8645)
- [Xi Venture Capital](/institutions/xi-venture-capital)
- [Xinjiye](/institutions/xinjiye)
- [Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership)](/institutions/yuanxihaihe-tianjin-biotechnology-pharmaceutical-industry-fund-partnership-limited-partnership)
- [Zhongxinjian Investment Ben](/institutions/zhongxinjian-investment-ben)
- [iRegene](/companies/UB-C5987)

## Sources

- No source links are available for this profile.